Advertising to Drive MannKind (MNKD) Afrezza Awareness and Adoption in Q3, Jefferies Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
MannKind (MNKD) Gains Amid Ongoing Talk of Short Squeeze
June 8, 2015 9:51 AM EDTMannKind (NASDAQ: MNKD) advanced over 5% Monday, extending recent gains amid ongoing talk of a squeeze in the heavily shorted name.
113 million shares of the stock were held short as of May 15, or about 42% of the float. Days to cover was 14.5 on average volume of 7.8 million.
... MoreMannKind (MNKD) Ticks Higher Despite Reports Affreza Difficult to Obtain
June 3, 2015 1:42 PM EDTMannKind (NASDAQ: MNKD) shares gained Wednesday, rising over 5%. Earlier its inhaled insulin drug Afrezza was featured in an article in the LA Times that discussed difficulties diabetes are having getting the drug due to doctor reluctance to prescribe it, as well as issues... More
